GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer

CAR-T Digest - August 2020

27 October 2025: GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer

GSK secured exclusive global rights from Syndivia to develop and commercialize a preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC)
The acquired ADC leverages Syndivia’s GeminiMab conjugation technology, demonstrating enhanced anti-tumour activity and a favourable safety profile in preclinical models
This strategic acquisition strengthens GSK’s prostate cancer portfolio, complementing its existing B7-H3-targeted ADC, GSK’227, and broad oncology pipeline
The novel ADC aims to address a major unmet need in mCRPC, offering potential for improved tumour targeting and tolerability compared to current standard treatments
GSK’s oncology R&D leadership emphasized the company’s commitment to advancing tumour-targeted technologies and expanding innovative treatment options in prostate cancer